Marketing Authorization Application(MAA)
The formal application to the European Medicines Agency or EU national authorities seeking authorization to market a medicinal product in the EU.
Usage Examples
- The sponsor filed an MAA via the Centralised Procedure after completion of the US NDA.
- CHMP issued a positive opinion on the MAA after two clock-stop cycles.
- The accelerated assessment MAA pathway reduced review to 150 active days.
What is MAA?
A Marketing Authorization Application (MAA) is the European Union equivalent of a US New Drug Application or Biologics License Application. It is submitted to obtain authorization to place a medicinal product on the EU market. MAAs can be filed through four procedures: the Centralised Procedure (required for biotech products, orphan drugs, advanced therapies, and products for certain diseases), the Decentralised Procedure (for submissions to multiple EU member states simultaneously), the Mutual Recognition Procedure, or a purely National Procedure.
The Centralised Procedure is reviewed by the European Medicines Agency (EMA), with the Committee for Medicinal Products for Human Use (CHMP) issuing a scientific opinion. The European Commission then grants or refuses marketing authorization valid across all EU member states, plus Iceland, Liechtenstein, and Norway.
Standard CHMP review takes 210 days of active assessment plus clock stops for applicant responses. Accelerated assessment and conditional marketing authorization pathways are available for products addressing unmet medical need. The eCTD format is required for all MAA submissions.
Regulatory Context
This term appears most often in submission & approval workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside REGULATION EC 726 2004, DIRECTIVE 2001 83 EC.
When This Matters
- The sponsor filed an MAA via the Centralised Procedure after completion of the US NDA.
- CHMP issued a positive opinion on the MAA after two clock-stop cycles.
- The accelerated assessment MAA pathway reduced review to 150 active days.
Common Mistakes
- Treating submission readiness as a formatting-only check without lifecycle validation.
- Using outdated guidance references across modules and summaries.
- Missing cross-functional review between RA, CMC, and quality before submission.
Related Regulations
Frequently Asked Questions
An MAA is the EU marketing authorization application filed to EMA or national EU authorities; an NDA is the US FDA new drug application. They cover different jurisdictions with overlapping but distinct content requirements. Sponsors filing globally typically prepare both in parallel using shared ICH CTD content.
The Centralised Procedure is mandatory for biotechnology products, advanced therapy medicinal products, orphan medicinal products, and drugs for HIV, cancer, diabetes, neurodegenerative disorders, autoimmune diseases, and viral diseases. Other products may use the Centralised Procedure optionally.
Standard Centralised Procedure review takes 210 days of EMA active assessment time plus clock stops during applicant responses. Total elapsed time typically runs 12-15 months. Accelerated assessment reduces active review to 150 days.
Related Terms
Related Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
Track ICH quality guidelines automatically and get alerts when changes impact your products
Related Regulatory Intelligence
Related Actions
Sources & References
